RAPT Therapeutics (RAPT.US) Latest Stock News - Major News Analysis - Longbridge

Quote List Quote List

Event Tracking

Nov7

RAPT Therapeutics released FY2025 9 Months earnings on November 6, 2025 (EST), actual revenue USD 0, actual EPS USD -1.9441

04:00

RAPT Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.652 (forecast USD -0.8189)

04:00

Oct27

Rapt Therapeutics Launches 2B Phase Clinical Trial of OZUREPRUBART for Food Allergy Patients

13:32

Oct25

Slutsky Maintains Buy Rating on RAPT Therapeutics

14:36

Oct22

Smith Rates RAPT Therapeutics Strong Buy with Price Target at $48.63

08:52

Oct20

JPMorgan Raises Rapt Therapeutics' Stock Rating to Overweight

17:27

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -17.58 M, EPS -0.652

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -17.64 M, EPS -0.6546

Jun17

Reverse Stock Split(EST)

1-for-8 Reverse Stock Split

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More